Belpointe Asset Management LLC Purchases Shares of 1,560 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Belpointe Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,560 shares of the biotechnology company’s stock, valued at approximately $121,000.

Other institutional investors also recently modified their holdings of the company. Corsicana & Co. acquired a new position in Sarepta Therapeutics during the 2nd quarter valued at approximately $31,000. Kistler Tiffany Companies LLC acquired a new position in Sarepta Therapeutics during the 2nd quarter valued at approximately $32,000. GPS Wealth Strategies Group LLC acquired a new position in Sarepta Therapeutics during the 2nd quarter valued at approximately $35,000. Jacobi Capital Management LLC increased its stake in Sarepta Therapeutics by 54.2% during the 1st quarter. Jacobi Capital Management LLC now owns 780 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 274 shares in the last quarter. Finally, Sowell Financial Services LLC increased its stake in Sarepta Therapeutics by 24.1% during the 1st quarter. Sowell Financial Services LLC now owns 869 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 169 shares in the last quarter. Institutional investors and hedge funds own 79.33% of the company’s stock.

SRPT opened at $85.63 on Friday. The company has a quick ratio of 4.70, a current ratio of 5.33 and a debt-to-equity ratio of 2.25. The company has a market cap of $6.84 billion, a price-to-earnings ratio of -10.68 and a beta of 1.38. Sarepta Therapeutics, Inc. has a 52-week low of $65.30 and a 52-week high of $181.83. The firm’s fifty day simple moving average is $74.92 and its two-hundred day simple moving average is $76.43.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.27. The business had revenue of $164.09 million for the quarter, compared to the consensus estimate of $161.95 million. Sarepta Therapeutics had a negative net margin of 105.73% and a negative return on equity of 94.90%. The company’s revenue was up 19.5% compared to the same quarter last year. During the same period last year, the firm posted ($1.93) earnings per share. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post -7.46 EPS for the current year.

A number of analysts have recently weighed in on SRPT shares. Guggenheim upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating in a research note on Wednesday. Morgan Stanley cut their price objective on shares of Sarepta Therapeutics from $93.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Monday, August 16th. Berenberg Bank started coverage on shares of Sarepta Therapeutics in a research note on Thursday, July 1st. They issued a “hold” rating and a $85.00 price objective on the stock. Credit Suisse Group increased their price objective on shares of Sarepta Therapeutics from $72.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, August 5th. Finally, Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $84.00 price objective on the stock in a research note on Wednesday, August 11th. Eleven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $125.39.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Featured Story: Technical Analysis

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.